The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1361-1368

  Wu, Xiaoli ^a,b   Huang, Zeping ^c   Han, Hongying ^b   Zhong, Zhiyong ^b   Gan, Zhaoyu ^b   Guo, Xiaofeng ^a   Diao, Feici ^b   Han, Zili ^b   Zhao, Jingping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antipsychotic discontinuation; Antipsychotic treated; Drug na ve; Glucose; Lipid; Schizophrenia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84905035831     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S63140     Document Type: Article

References (50)

1. Osby U, Correia N, Brandt L, Ekbom A, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
2. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care. 2007;13(7 Suppl):S170-S177.
3. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
4. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry. 2004;65(5):715-720.
5. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6): 1115-1121.
6. Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(22): 2644-2650.
7. Cohn T, Prud'Homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49(11):753-760.
8. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71(3):239-257.
9. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res. 2007;90(1-3):162-173.
10. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro. Eur Neuropsychopharmacol. 2004;14(2):115-119.
11. Smith RC, Lindenmayer JP, Bark N, et al. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol. 2005;8(2):183-194.
12. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry. 1994;151(10):1520-1521.
13. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1(8636):495.
14. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat 10. 1995;(193 Pt 1):1-260.
15. Yang J, Liu X, Liu X, et al. Abnormality of glycometabolism related factors in non-psychotic offspring of schizophrenic patients. Psychiatry Res. 2012;198(2):183-186.
16. Spelman LM, Walsh PI, Sharifi N, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007;24(5):481-485.
17. Guest PC, Wang L, Harris LW, et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry. 2010;15(2):118-119.
18. Dasgupta A, Singh OP, Rout JK, et al. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1202-1207.
19. Freeman H. Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry. 1946;56(1):74-78.
20. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001;11(1):25-32.
21. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111(9):716-723.
22. Melkersson KI, Dahl ML, Hulting AL. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucoseinsulin homeostasis and lipid metabolism. Psychopharmacology (Berl). 2004;175(1):1-6.
23. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-1711.
24. Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191:23-29.
25. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28(2):132-137.
26. Patel NC, Hariparsad M, Matias-Akthar M, et al. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol. 2007;17(3):303-311.
27. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry. 1999;156(8): 1270-1272.
28. Leitao-Azevedo CL, Guimaraes LR, de Abreu MG, et al. Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Rev Bras Psiquiatr. 2006;28(4):301-304.
29. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087-1092.
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
31. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry. 2007;41(7):606-610.
32. Wang G, Li YF. [Association between lipoprotein(a) and coronary artery disease]. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(7):618-620.
33. Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of secondgeneration antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111(1-3):9-16.
34. Perez-Iglesias R, Crespo-Facorro B, Amado JA, et al. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry. 2007;68(11):1733-1740.
35. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543.
36. Ryan MM, Huffaker SJ, Webster MJ, et al. Application and optimization of microarray technologies for human postmortem brain studies. Biol Psychiatry. 2004;55(4):329-336.
37. Yogaratnam J, Biswas N, Vadivel R, et al. Metabolic complications of schizophrenia and antipsychotic medications-an updated review. East Asian Arch Psychiatry. 2013;23(1):21-28.
38. Chadda RK, Ramshankar P, Deb KS, et al. Metabolic syndrome in schizophrenia: differences between antipsychotic-naive and treated patients. J Pharmacol Pharmacother. 2013;4(3):176-186.
39. Wu X, Huang Z, Wu R, et al. The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res. 2013;150(1): 157-162.
40. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
41. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007;32(12): 2561-2569.
42. Henderson DC, Fan X, Sharma B, et al. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. J Psychiatr Pract. 2009;15(4):251-261.
43. Onat A, Avci GS, Barlan MM, et al. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord. 2004;28(8):1018-1025.
44. Jia WP, Lu JX, Xiang KS, et al. Prediction of abdominal visceral obesity from body mass index, waist circumference and waist-hip ratio in Chinese adults: receiver operating characteristic curves analysis. Biomed Environ Sci. 2003;16(3):206-211.
45. Shen W, Punyanitya M, Chen J, et al. Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring). 2006;14(4):727-736.
46. Ho SC, Chen YM, Woo JL, et al. Association between simple anthropometric indices and cardiovascular risk factors. Int J Obes Relat Metab Disord. 2001;25(11):1689-1697.
47. Farin HM, Abbasi F, Reaven GM. Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake. Metabolism. 2005;54(10):1323-1328.
48. Farin HM, Abbasi F, Reaven GM. Body mass index and waist circumference both contribute to differences in insulin-mediated glucose disposal in nondiabetic adults. Am J Clin Nutr. 2006;83(1):47-51.
49. Farin HM, Abbasi F, Reaven GM. Comparison of body mass index versus waist circumference with the metabolic changes that increase the risk of cardiovascular disease in insulin-resistant individuals. Am J Cardiol. 2006;98(8):1053-1056.
50. Dalton M, Cameron AJ, Zimmet PZ, et al. Waist circumference, waisthip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med. 2003;254(6): 555-563.